Last reviewed · How we verify
high sodium diet
high sodium diet is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | high sodium diet |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Effect of the DASH Diet on Clinical and Metabolic Parameters in Children With MASLD (NA)
- Genetic Architecture of Natriuretic Peptides and Blood Pressure Response (NA)
- Mechanisms Underlying the Protective Vascular Effects of Dietary Potassium in Humans (NA)
- Sodium vs Potassium Education to Improve Vascular Health (NA)
- A Community Health Worker-Led LSSS Intervention in Bangladesh (NA)
- Impact of Dietary Phosphate Excess on Exercise Capacity and Visceral Adiposity (NA)
- Vascular Effects of High-Salt After Preeclampsia (EARLY_PHASE1)
- Sodium-rich COndiments Unifying Health and Taste (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- high sodium diet CI brief — competitive landscape report
- high sodium diet updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about high sodium diet
What is high sodium diet?
Who makes high sodium diet?
What development phase is high sodium diet in?
Related
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing